Pharmacists in Smoking Cessation

Recommendations

Info

A maintenance bronchodilator therapy for your symptomatic COPD patients Don’t wait - prescribe Anoro Ellipta instead of tiotropium. Give your patients the immediate results they need. 1-2 Visit www.anoro.ie to find out more Anoro is contraindicated for patients who are hypersensitive to the active substances or to any of the excipients. Anoro should not be used in patients with asthma 3 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Anoro ® (umeclidinium bromide/vilanterol [as trifenatate]) Prescribing information (Please consult the full Summary of Product Characteristics (SmPC) before prescribing) Anoro ® 55/22 mcg (umeclidinium bromide/vilanterol [as trifenatate]) inhalation powder. Each single inhalation of umeclidinium bromide (UMEC) 62.5 micrograms (mcg) and vilanterol (VI) 25 mcg provides a delivered dose of UMEC 55 mcg and VI 22 mcg. Indications: COPD: Maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD. Dosage and administration: Inhalation only. COPD: One inhalation once daily of Anoro. Contraindications: Hypersensitivity to the active substances or to any of the excipients (lactose monohydrate and magnesium stearate). Precautions: Anoro should not be used in patients with asthma. Treatment with Anoro should be discontinued in the event of paradoxical bronchospasm and alternative therapy initiated if necessary. Cardiovascular effects may be seen after the administration of muscarinic receptor antagonists and sympathomimetics therefore Anoro should be used with caution in patients with severe cardiovascular disease. Anoro should be used with caution in patients with urinary retention, narrow angle glaucoma, convulsive disorders, thyrotoxicosis, hypokalaemia, hyperglycaemia and severe hepatic impairment. No dosage adjustment is required in renal or mild to moderate hepatic impairment. Acute symptoms: Anoro is not indicated for acute episodes of bronchospasm. Warn patients to seek medical advice if short-acting inhaled bronchodilator use increases, a re-evaluation of the patient and of the COPD treatment regimen should be undertaken. Interactions with other medicinal products: Interaction studies have only been performed in adults. Avoid ß-blockers. Caution is advised when co-administering with strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, itraconazole, ritonavir, telithromycin). Anoro should not be used in conjunction with other long-acting ß 2-adrenergic agonists or medicinal products containing long-acting muscarinic antagonists. Caution is advised with concomitant use with methylxanthine derivatives, steroids or non-potassium-sparing diuretics as it may potentiate possible hypokalaemic effect of ß 2-adrenergic agonists. Fertility, pregnancy, and breast-feeding: No available data. Balance risks against benefits. Side effects: Common: Urinary tract infection, sinusitis, nasopharyngitis, pharyngitis, upper respiratory tract infection, headache, cough, oropharyngeal pain, constipation and dry mouth. Uncommon: Hypersenstivity reactions including rash; trenor, dysgeusia, atrial fibrillation, supraventricular tachycardia, rhythm idioventricular, tachycardia, supraventricular extrasystoles and palpitations. Rare: Anaphylaxis, angioedema, urticaria, urinary retention, dysuria and bladder outlet obstruction. Frequency unknown: Glaucoma. Marketing Authorisation (MA) Holder: Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK. MA Nr: 55/22 mcg 1x30 doses [EU/1/14/898/002]. Legal category: POM B. Last date of revision: Oct 2016. Job Ref: IE/UCV/0063/15 (2). Further information available on request from GlaxoSmithKline, 12 Riverwalk, Citywest Business Campus, Dublin 24, Tel: 01-4955000. Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at www.hpra.ie. Adverse reactions can also be reported to the HPRA by calling (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255. References: 1. Donohue JF et al. Respir Med 2013; 107: 1538–1546. 2. Maleki-Yazdi MR et al. Respir Med 2014; 105: 1752-1760. 3. Anoro Ellipta Summary of Product Characteristics. Available from: www.medicines.ie. Accessed: November 2016. ANORO ELLIPTA was developed in collaboration with IE/UCV/0075/15(2) Date of Preparation: November 2016 ©2016 GSK group of companies. All rights reserved.
FEBRUARY 2017 05 A Note from the Editor IPU News The latest news and events from Butterfield House The IPU Review is published monthly and circulated to Irish pharmacists. The views expressed by contributors are not those of the IPU nor is responsibility accepted for claims in articles or advertisements. 08 IPU Academy Spring Programme 08 IPU Academy Webinar Series 08 Pharmacy in the Media 09 Dates for your Diary 10 IPU Business Academy Spring Programme 2017 Subscription: €95 (Ireland North & South) and €140 (including postage overseas). Publisher: Irish Pharmacy Union (IPU Services Ltd), Butterfield House, Butterfield Avenue, Rathfarnham, Dublin 14, D14 E126 Tel: (01) 493 6401 Fax: (01) 493 6626 Email: ipureview@ipu.ie Website: www.ipu.ie Editor: Jack Shanahan MPSI Editorial Associates: Aoibheann Ní Shúilleabháin, Jim Curran and Ciara Browne Advertising: Aoibheann Ní Shúilleabháin Email: ipureview@ipu.ie Tel: (01) 493 6401 ©2017 Copyright: All Rights Reserved, Irish Pharmacy Union. Printed by Ryson Colour Printers Ltd. IPU Review is a Registered Trademark of the Irish Pharmacy Union. Features 12 Role of Pharmacists in Smoking Cessation 16 Crime against Pharmacies Reaching Crisis Levels Key findings from the IPU’s Annual Pharmacy Crime Survey 2016 20 Stop that Thief! A brief overview of defamation and some practical advice as to how to protect yourself 16 12 IPUREVIEW FEBRUARY 2017 3
Page 1: IRELAND’S OFFICIAL PHARMACY PUBLI
Page 5 and 6: 24 Interview with Jonathon Morrisse
Page 7 and 8: A NOTE FROM THE EDITOR Jack Shanaha
Page 9 and 10: NEW THIS MONTH! Letters to the Edit
Page 11 and 12: IPU NEWS IPU Business Programme Sch
Page 13 and 14: encouragement, and typically takes
Page 15 and 16: MINI 3 * MINUTES START TO RELIEVE C
Page 17 and 18: n 75% of respondents are aware of t
Page 19 and 20: of a similar shape and size and tha
Page 21 and 22: What is defamation? A defamatory st
Page 23 and 24: • Ireland’s only compounding fa
Page 25 and 26: don’t look inflamed and there are
Page 27 and 28: Your Preferred Partner MAJORITY OF
Page 29 and 30: For ANY Cough AT HOME syrup ON THE
Page 31 and 32: 5-7 May 2017 | Croke Park, Dublin R
Page 33 and 34: PROGRAMME INFORMATION The IPU NATIO
Page 35 and 36: IPU - The voice of community pharma
Page 37 and 38: nd Immune r Life
Page 40 and 41: CPD overview Self-appraisal What do
Page 42: CLINICAL TIPS Tara Kelly, IPU Produ
Page 45 and 46: IPU PRODUCT FILE The IPU Product Fi
Page 47 and 48: departments that look after these a
Page 49 and 50: Tailor-made just for your pharmacy
Page 51 and 52: Now, this saver has learned the les
Page 53 and 54:
Dates have just been announced for
Page 55 and 56:
EHC to be made available to Medical
Page 57 and 58:
ME drug not authorised by European
Page 59 and 60:
Nivolumab approved in Europe for tr
Page 61 and 62:
NEWS HIQA publishes standards for a
Page 63 and 64:
NEWS Eileen Byrne appointed Managin
Page 65 and 66:
NEWS New Year - New Lungs with We L
Page 67 and 68:
SEMINAR CLASSIFIEDS NEW Insurance S
show all

Pharmacists in Smoking Cessation

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?